149
Participants
Start Date
July 29, 2020
Primary Completion Date
August 16, 2021
Study Completion Date
August 16, 2021
M5049
Participants received M5049 50 milligram (mg) orally twice daily for 14 days.
M5049
Participants received M5049 100 mg orally twice daily for 14 days.
Placebo
Participants received placebo tablets matched to M5049 daily for 14 days.
Henry Ford Medical Center, Detroit
Christus Spohn Hospital Corpus Christi-Memorial, Corpus Christi
LAC-USC Medical Center, Los Angeles
Sharp Chula Vista Medical Center, San Diego
Holy Name Hospital - Dept of Multiple Sclerosis Comp Care Center, Teaneck
Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte
Hospital Dia do Pulmão, Blumenau
Hospital São José - Sociedade Literária e Caritativa Santo Agostinho, Criciúma
Hospital de Clínicas de Porto Alegre, Porto Alegre
HMCG - Hospital e Maternidade Dr. Christovão da Gama, Santo André
Pesquisare, Santo André
Hospital Alemão Oswaldo Cruz, São Paulo
Hospital Bandeirantes / Hospital Leforte Liberdade, São Paulo
Hospital Leforte Morumbi, São Paulo
Instituto de Infectologia Emílio Ribas, São Paulo
Manila Doctors Hospital, Manila
Medical Center Manila - Medicine, Manila
Lung Center of the Philippines - Medicine, Quezon
Quirino Memorial Medical Center, Quezon
Veterans Memorial Medical Center, Quezon
East Avenue Medical Center, Quezon City
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY